Palesh Mohammad, Jonsson Pia Maria, Jamshidi Hamidreza, Wettermark Björn, Tomson Göran, Fredrikson Sten
Division of International Health (IHCAR), Department of Public Health Sciences, Karolinska Institutet, Sweden.
Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):934-41. doi: 10.1002/pds.1621.
There are few studies on the diffusion of expensive new therapies in low- or middle-income countries. The objectives of this study were to describe the diffusion of interferon beta for the treatment of patients with multiple sclerosis (MS) in Iran and to analyze its use in a cohort of 890 patients in Tehran registered in the Iranian MS Society (IMSS) registry.
Data on the diffusion of interferon beta drugs from 2000 to 2004 in Iran were obtained from the Ministry of Health (MOH). Data on the utilization of interferon beta in selected patient groups were collected from routine clinical data of the IMSS in a sample of population in Tehran province from 2003 to 2005.
Interferon beta had a rapid diffusion in Iran during the study period, and it was used in all 28 provinces in 2004, however, much less in the poor provinces. Interestingly, interferon beta was prescribed to 68% of the patients in Tehran registered in the IMSS registry during 2003-2005. The usage of interferon beta as registered in the IMSS was higher (p < 0.0001) among insured than uninsured patients.
The use of interferon beta treatment has grown considerably in Iran. In Tehran, interferon beta seems to be mainly used by young ambulatory patients with relapsing-remitting MS, indicating a rational drug use.
关于昂贵的新疗法在低收入或中等收入国家的传播情况，相关研究较少。本研究的目的是描述干扰素β在伊朗用于治疗多发性硬化症（MS）患者的传播情况，并分析其在伊朗MS协会（IMSS）登记的德黑兰890名患者队列中的使用情况。
2000年至2004年伊朗干扰素β药物传播的数据来自卫生部（MOH）。2003年至2005年，从德黑兰省部分人群的IMSS常规临床数据中收集选定患者群体中干扰素β的使用数据。
在研究期间，干扰素β在伊朗迅速传播，2004年在所有28个省份都有使用，但在贫困省份使用较少。有趣的是，2003年至2005年期间，在IMSS登记的德黑兰患者中，68%的患者使用了干扰素β。在IMSS登记的有保险患者中，干扰素β的使用率高于无保险患者（p < 0.0001）。
在伊朗，干扰素β治疗的使用有了显著增长。在德黑兰，干扰素β似乎主要用于复发缓解型MS的年轻门诊患者，表明用药合理。
